Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
56.9M
-
Shares change
-
+9.51M
-
Total reported value, excl. options
-
$882M
-
Value change
-
+$147M
-
Number of buys
-
17
-
Number of sells
-
-28
-
Price
-
$16.70
Significant Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q3 2021
53 filings reported holding CNTA - Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share as of Q3 2021.
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.9M shares
of 147M outstanding shares and own 38.63% of the company stock.
Largest 10 shareholders include Medicxi Ventures Management (Jersey) Ltd (17.9M shares), GENERAL ATLANTIC, L.P. (9.68M shares), JANUS HENDERSON GROUP PLC (5.61M shares), Vida Ventures Advisors, LLC (3.93M shares), RA CAPITAL MANAGEMENT, L.P. (3.58M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.02M shares), Cormorant Asset Management, LP (1.73M shares), Samsara BioCapital, LLC (1.54M shares), BOXER CAPITAL, LLC (1.33M shares), and BAKER BROS. ADVISORS LP (1.13M shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.